STOCK TITAN

Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Inspira Technologies (Nasdaq: IINN) has appointed Tal Parnes as the new chairman of the board, effective February 1, 2025. Parnes, who has served as an independent director since July 2021, brings over 30 years of experience in technology, particularly in medical technology and pharmaceuticals. He succeeds Prof. Benad Goldwasser, who resigned for personal reasons.

Parnes' background includes co-founding and serving as CEO of Zuta-Core and HQL Pharmaceuticals , along with executive roles at several technology companies. The appointment aims to enhance Inspira's leadership and market position.

The company recently achieved significant milestones with its INSPIRA ART100 system receiving FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in June and July 2024.

Inspira Technologies (Nasdaq: IINN) ha nominato Tal Parnes come nuovo presidente del consiglio, con effetto dal 1 febbraio 2025. Parnes, che ha ricoperto il ruolo di direttore indipendente da luglio 2021, porta con sé oltre 30 anni di esperienza nel settore tecnologico, in particolare nella tecnologia medica e nei prodotti farmaceutici. Succede al Prof. Benad Goldwasser, che si è dimesso per motivi personali.

Il background di Parnes include la co-fondazione e la direzione come CEO di Zuta-Core e HQL Pharmaceuticals, insieme a ruoli esecutivi in diverse aziende tecnologiche. Questa nomina mira a migliorare la leadership e la posizione di mercato di Inspira.

Recentemente, l'azienda ha raggiunto importanti traguardi con il suo sistema INSPIRA ART100, che ha ricevuto l'autorizzazione FDA 510(k) per le procedure CBP e la certificazione AMAR israeliana per le procedure di ossigenazione a membrana extracorporea e bypass cardiopolmonare a giugno e luglio 2024.

Inspira Technologies (Nasdaq: IINN) ha nombrado a Tal Parnes como nuevo presidente del consejo, a partir del 1 de febrero de 2025. Parnes, que ha sido director independiente desde julio de 2021, aporta más de 30 años de experiencia en tecnología, especialmente en tecnología médica y farmacéutica. Sucede al Prof. Benad Goldwasser, quien renunció por motivos personales.

La trayectoria de Parnes incluye la co-fundación y el cargo de CEO en Zuta-Core y HQL Pharmaceuticals, además de roles ejecutivos en varias empresas tecnológicas. La designación tiene como objetivo mejorar el liderazgo y la posición de mercado de Inspira.

Recientemente, la empresa logró hitos significativos con su sistema INSPIRA ART100, que recibió la aprobación 510(k) de la FDA para procedimientos de CBP y la certificación AMAR israelí para procedimientos de oxigenación por membrana extracorpórea y bypass cardiopulmonar en junio y julio de 2024.

Inspira Technologies (Nasdaq: IINN)은 2025년 2월 1일부터 Tal Parnes를 새로운 이사회 의장으로 임명했습니다. Parnes는 2021년 7월부터 독립 이사로 재직했으며, 의료 기술 및 제약 분야에서 30년 이상의 경력을 보유하고 있습니다. 그는 개인적인 사유로 사임한 Benad Goldwasser 교수의 후임이 됩니다.

Parnes의 경력에는 Zuta-Core 및 HQL Pharmaceuticals의 공동 창립 및 CEO로 재직한 것과 여러 기술 회사에서의 경영직이 포함됩니다. 이번 임명은 Inspira의 리더십과 시장 위치를 강화하는 것을 목표로 하고 있습니다.

회사는 최근 INSPIRA ART100 시스템이 2024년 6월과 7월에 CBP 절차를 위한 FDA 510(k) 승인을 받고 이스라엘 AMAR 인증을 획득하는 등의 중요한 이정표를 달성했습니다.

Inspira Technologies (Nasdaq: IINN) a nommé Tal Parnes comme nouveau président du conseil, à compter du 1er février 2025. Parnes, qui occupe le poste de directeur indépendant depuis juillet 2021, apporte plus de 30 ans d'expérience dans le domaine de la technologie, en particulier dans la technologie médicale et pharmaceutique. Il succède au Prof. Benad Goldwasser, qui a démissionné pour des raisons personnelles.

Le parcours de Parnes comprend la co-fondation et la direction en tant que PDG de Zuta-Core et HQL Pharmaceuticals, ainsi que des postes de direction dans plusieurs entreprises technologiques. Cette nomination vise à renforcer le leadership et la position de marché d'Inspira.

L'entreprise a récemment atteint des jalons significatifs avec son système INSPIRA ART100 ayant reçu l'approbation FDA 510(k) pour les procédures CBP et la certification AMAR israélienne pour les procédures d'oxygénation par membrane extracorporelle et de contournement cardiopulmonaire en juin et juillet 2024.

Inspira Technologies (Nasdaq: IINN) hat Tal Parnes zum neuen Vorsitzenden des Aufsichtsrats ernannt, mit Wirkung zum 1. Februar 2025. Parnes, der seit Juli 2021 als unabhängiger Direktor tätig ist, bringt über 30 Jahre Erfahrung in der Technologiebranche, insbesondere im Bereich Medizintechnik und Pharmazie, mit. Er tritt die Nachfolge von Prof. Benad Goldwasser an, der aus persönlichen Gründen zurückgetreten ist.

Parnes' Hintergrund umfasst die Mitgründung und die Funktion als CEO von Zuta-Core und HQL Pharmaceuticals sowie Führungspositionen in mehreren Technologieunternehmen. Die Ernennung zielt darauf ab, die Führung und Marktposition von Inspira zu stärken.

Das Unternehmen hat kürzlich bedeutende Meilensteine erreicht, indem sein INSPIRA ART100 System im Juni und Juli 2024 die FDA 510(k) Genehmigung für CBP-Verfahren sowie die israelische AMAR-Zertifizierung für Verfahren zur extrakorporalen Membranoxygenierung und Herz-Lungen-Überbrückung erhalten hat.

Positive
  • FDA 510(k) clearance obtained for INSPIRA ART100 system
  • Israeli AMAR certification received for multiple procedures
  • New chairman brings 30+ years of relevant industry experience
  • Previous board experience with company since July 2021
Negative
  • None.

RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.

 

Mr. Tal Parnes, Chairman of the Board of Directors, Inspira Technologies

 

Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision.

As a serial entrepreneur, Parnes has demonstrated his ability to drive innovation and growth across various high-tech sectors, including medical technology, communications and defense. Mr. Parnes is familiar with the Company and its technology, having served as an independent director of the Company since July 2021.

Mr. Parnes is a veteran executive in the medical technology industry. He co-founded and is the former chief executive officer and president at Zuta-Core Ltd. and HQL Pharmaceuticals Ltd. Mr. Parnes also served as chief operating officer at Silynx Communications Inc. as a vice president of operations at Wavion Inc. and Atrica Ltd. He also served as chief financial officer and director of business development of Printlife Ltd.

The appointment of Mr. Parnes as chairman of the board of directors will enhance the Company's leadership. Mr. Parnes' unwavering commitment to integrating his vast knowledge of emerging technologies and market trends will be invaluable. Mr. Parnes' leadership will not only refine the Company's strategic vision but also bolster the Company's competitive advantage in the market, positioning the Company for sustainable success in the future. The Company is eager to harness Mr. Parnes' insights and experience as the Company reaches new heights.

The Company would like to thank Prof. Benad Goldwasser, MD, for his leadership role as chairman of the board of directors since 2021. The Company extends its gratitude for his numerous activities and contributions to the Company, spanning business, medical, and administrative aspects. Prof. Goldwasser provided invaluable support during the Company's Nasdaq Capital Market listing and leveraged his extensive network of connections from his years of experience. The Company accepted Prof. Goldwasser's resignation from his position, which was  due to personal reasons.

 

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake during treatment. The INSPIRA ART is being equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions.

In June and July 2024, respectively, the Company's INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans nor approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential positive outcome of Mr. Parnes' appointment. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Photo - https://mma.prnewswire.com/media/2602501/Tal_Parnes.jpg
Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

 

(PRNewsfoto/Inspira Technologies)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inspira-announces-the-appointment-of-tal-parnes-as-the-new-chairman-of-the-board-bringing-vast-experience-in-the-medical-technology-and-pharmaceutical-sectors-302356143.html

SOURCE Inspira Technologies

FAQ

When will Tal Parnes begin his role as chairman of IINN?

Tal Parnes will begin his role as chairman of Inspira Technologies (IINN) effective February 1, 2025.

What regulatory approvals has IINN's INSPIRA ART100 system received in 2024?

In 2024, IINN's INSPIRA ART100 system received FDA 510(k) clearance for CBP procedures in June and Israeli AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in July.

What is Tal Parnes' previous experience with IINN?

Tal Parnes has served as an independent director of Inspira Technologies (IINN) since July 2021.

Why did the previous IINN chairman step down?

Prof. Benad Goldwasser stepped down as chairman of IINN due to personal reasons.

What is the market potential for IINN's INSPIRA ART technology?

IINN's INSPIRA ART technology targets the $19 billion mechanical ventilation market, with potential to serve 20 million ICU patients with acute respiratory failure annually.

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares

NASDAQ:IINN

IINN Rankings

IINN Latest News

IINN Stock Data

26.44M
20.75M
7.32%
4.97%
1.51%
Medical Devices
Healthcare
Link
United States of America
Ra'anana